表紙
市場調査レポート

がんワクチン:技術と世界の市場

Cancer Vaccines: Technologies and Global Markets

発行 BCC Research 商品コード 320804
出版日 ページ情報 英文 116 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
がんワクチン:技術と世界の市場 Cancer Vaccines: Technologies and Global Markets
出版日: 2015年01月01日 ページ情報: 英文 116 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

2013年における世界のがんワクチン市場は約45億米ドルとなりました。同市場は2014年に約40億米ドルに達し、2014年から2019年の期間中は1.3%のCAGRを記録し、2019年に43億米ドルに達すると予測されています。

当レポートでは、世界のがんワクチン市場について調査し、世界市場とがんワクチン技術の概要、市場動向の分析と予測、政府・規制環境の調査、市場影響因子および市場機会の分析、特許動向、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • 定義
  • がんの歴史とその管理
  • がんの分類
  • がんの症状
  • リスク因子
  • 発がん物質
  • 市販のがんワクチン
  • 有病率
  • 発症率・死亡率
  • がん統計:地域別
  • 世界のがん統計:がんタイプ別
  • がん統計の各種フォーム:地域別
  • がんと免疫システム
  • がんの分子生物学
  • がんの病態生理学
  • がんの有病率
  • がんの管理
  • がんワクチン
  • ワクチン製造
  • がんワクチンのタイプ

第4章 規制の側面

  • 認可済みがんワクチンの規制の歴史
  • リコール
  • オーファンドラッグ指定
  • その他の重要な規制属面

第5章 新たな開発

  • 前立腺がん
  • 乳がん
  • 子宮頸がん
  • 肝臓がん
  • 肺がん
  • 胃がん
  • 大腸がん
  • 食道がん

第6章 がんワクチンの市場分析

  • 市場:種類別
  • 市場シェア
  • 市場:地域別
  • 治療用ワクチン
  • 予防用ワクチン
  • 産業構造
  • 予防用がんワクチン
  • 治療用がんワクチン

第7章 市場:がんタイプ別

  • 世界市場:がんタイプ別
  • 市場収益
  • 市場シェア
  • 前立腺がん
  • 肝臓がん
  • 子宮頸がんワクチン

第8章 特許分析

  • 年度別
  • タイプ/分類別
  • 企業別
  • 特許所有者の国別
  • 出願タイプ別

第9章 現況

  • がんワクチンの影響因子

第10章 企業プロファイル

  • ADAMIS PHARMACEUTICALS CORP.
  • ADURO BIOTECH INC.
  • ADVANTAGENE INC.
  • ADVAXIS INC.
  • ALPHAVAX HUMAN VACCINES INC.
  • ALTOR BIOSCIENCE CORP.
  • ANTIGEN EXPRESS INC.
  • BAVARIAN NORDIC A/S
  • BELLICUM PHARMACEUTICALS
  • BIOVEST INTERNATIONAL
  • CELLDEX THERAPEUTICS
  • CUREVAC GMBH
  • DENDREON
  • EMD SERONO
  • GALINA BIOPHARMA
  • GENEXINE INC.
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE INC.
  • GRADALIS INC.
  • HEAT BIOLOGICS INC.
  • IMMUNE CELL THERAPY INC. (ICT)
  • IMMUNICUM
  • IMMUNOFRONTIER INC.
  • IMMUNOVATIVE THERAPIES LTD.
  • INOVIO PHARMACEUTICALS
  • ISA PHARMACEUTICALS
  • KAEL-GEMVAX CO. LTD.
  • MERCK & CO.
  • NEWLINK GENETICS CORP.
  • NOVARX CORP.
  • ONCOTHYREON
  • ONCOVIR INC
  • OXFORD BIOMEDICA
  • SOTIO AS
  • UBIVAC LLC
  • VICAL INC.
  • VACCINOGEN INC.
  • VAXON BIOTECH

第11章 用語

図表

目次
Product Code: PHM173A

REPORT HIGHLIGHTS

The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019.

This report provides:

  • An overview of the global markets and technologies for cancer vaccines.
  • Analyses of global market trends, with data from 2012 and 2013, estimates for 2014, and projections of CAGRs through 2019.
  • Coverage of the cancer vaccines arena including diverse therapeutic platform technologies, immune-stimulating agents and approved vaccines for cancer.
  • Examination of the governmental and regulatory environment and how its effecting the market.
  • Information on new developments including products in Phase I-IV clinical trials, as well as new technologies.
  • Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.
  • Relevant patent analysis, presented by year and by vaccine type.

SCOPE OF THE STUDY

The scope of this study entails the current the market for cancer vaccines, which includes therapeutic cancer vaccines and preventive cancer vaccines. Human papillomavirus (HPV) vaccines and hepatitis B vaccines are also included; however, while such vaccines only indirectly act against cancer, they do aid in reducing the global cancer burden. The report also includes regulatory aspects, current and developing technologies, the demographics of cancer incidence, innovation and challenges, patent analyses, market projections and market share, along with latest trends and clinical trials.

Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis. Product information and the technologies/platforms discussed in the report are based on their present and prospective application and practicality. The report presents sales analyses broken down geographically for the United States, Europe and the emerging markets. The emerging markets include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. The application of cancer vaccines in various types of cancer is discussed from both commercial perspective and that of a research and development (R&D) perspective.

ANALYSTS' CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this report is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and she has worked with top companies in India and the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYSTS' CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • DEFINITIONS
  • HISTORY OF CANCER AND ITS MANAGEMENT
    • TABLE 1: HISTORY OF CANCER AND ITS MANAGEMENT
  • CLASSIFICATION OF CANCERS
    • CLASSIFICATION BY SITE OF ORIGIN
    • CLASSIFICATION BY TISSUE TYPE
      • Carcinoma
        • Adenocarcinoma
        • Squamous Cell Carcinoma
      • Sarcomas
      • Myeloma
      • Leukemias
      • Lymphomas
      • Mixed Types
    • CLASSIFICATION BY GRADE
  • SYMPTOMS OF CANCER
    • LOCAL SYMPTOMS
    • SYSTEMIC SYMPTOMS
    • SYMPTOMS OF THE SPREAD OF CANCER OR METASTASIS
  • RISK FACTORS
  • CANCER-CAUSING AGENTS
    • CHEMICAL CARCINOGENS
    • IONIZING RADIATION
    • VIRAL AND BACTERIAL INFECTIONS
    • GENETIC OR INHERITED CANCERS
    • HORMONAL CHANGES
    • IMMUNE SYSTEM DYSFUNCTION
  • COMMERCIALLY AVAILABLE CANCER VACCINES
    • LIVER CANCER
    • PROSTATE CANCER
      • Radical Retropubic Prostatectomy
      • Laparoscopic Prostatectomy
      • Radical Perineal Prostatectomy
      • Transurethral Resection of the Prostate
    • CERVICAL CANCER
  • PREVALENCE
    • TABLE 2: ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS)
  • INCIDENCE AND MORTALITY RATE
    • TABLE 3: GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012
  • CANCER STATISTICS BY GEOGRAPHY
    • TABLE 4: ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
    • TABLE 5: ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
  • GLOBAL CANCER STATISTICS BY TYPE OF CANCER
    • TABLE 6: ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS)
    • TABLE 7: ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS)
    • TABLE 8: ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS)
  • VARIOUS FORMS OF CANCER STATISTICS BY GEOGRAPHY
    • TABLE 9: ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012
    • TABLE 10: ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012
      • TABLE 11: ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012
  • CANCER AND THE IMMUNE SYSTEM
  • MOLECULAR BIOLOGY OF CANCER
  • CANCER PATHOPHYSIOLOGY
    • ONCOGENES
    • TUMOR SUPPRESSOR GENES
  • PREVENTION OF CANCER
  • MANAGEMENT OF CANCER
    • SURGERY
    • CHEMOTHERAPY
    • RADIATION THERAPY
    • TARGETED THERAPY
    • IMMUNOTHERAPY
    • HORMONAL THERAPY
    • BIOLOGICAL THERAPY
  • CANCER VACCINES
    • CLASSIFICATION OF CANCER VACCINES
      • Preventive (or Prophylactic) Vaccines
      • Therapeutic Vaccines
  • MANUFACTURING/CREATING VACCINES
  • TYPES OF CANCER VACCINES
    • Tumor Cell Vaccines
    • Cancer Stem Cell Vaccines
    • Peptide/Protein Vaccines
      • Antigen Vaccines
      • Anti-idiotype Vaccines
      • Heat Shock Protein Vaccines
      • DNA and Vector-Based Vaccines

CHAPTER 4 - REGULATORY ASPECTS

  • REGULATORY HISTORY OF APPROVED CANCER VACCINES
    • TABLE 12: REGULATORY APPROVALS OF CANCER VACCINES, THROUGH JULY 2014
  • RECALLS
    • TABLE 13: PRODUCT RECALLS, JAN. 2010 TO JULY 2014
  • ORPHAN DRUG DESIGNATION
    • TABLE 14: SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED FROM JAN. 2010 TO JULY 2014
  • OTHER SIGNIFICANT REGULATORY ASPECTS

CHAPTER 5 - NEW DEVELOPMENTS

  • PROSTATE CANCER
    • TABLE 15: CLINICAL TRIALS FOR PROSTATE CANCER VACCINES (NO.)
    • TABLE 16: SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT
  • BREAST CANCER
    • TABLE 17: CLINICAL TRIALS FOR BREAST CANCER VACCINES (NO.)
    • TABLE 18: SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT
  • CERVICAL CANCER
    • TABLE 19: CLINICAL TRIALS FOR CERVICAL CANCER VACCINES (NO.)
    • TABLE 20: SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT
  • LIVER CANCER
    • TABLE 21: CLINICAL TRIALS FOR LIVER CANCER VACCINES (NO.)
    • TABLE 22: SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT
  • LUNG CANCER
    • TABLE 23: CLINICAL TRIALS FOR LUNG CANCER VACCINES (NO.)
    • TABLE 24: SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER
  • STOMACH CANCER
    • TABLE 25: CLINICAL TRIALS FOR STOMACH CANCER VACCINES (NO.)
    • TABLE 26: SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT
  • COLORECTAL CANCER
    • TABLE 27: CLINICAL TRIALS FOR COLORECTAL CANCER VACCINES (NO.)
    • TABLE 28: SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT
  • ESOPHAGEAL CANCER
    • TABLE 29: CLINICAL TRIALS FOR ESOPHAGEAL CANCER VACCINES (NO.)
    • TABLE 30: SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT

CHAPTER 6 - MARKET ANALYSIS OF CANCER VACCINES

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUES
      • TABLE 31: GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2019 ($ MILLIONS)
      • FIGURE 1: GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2012-2019 ($ MILLIONS)
  • MARKET SHARES
    • TABLE 32: GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)
    • FIGURE 2: GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUES
      • TABLE 33: GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 3: GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
  • THERAPEUTIC VACCINES
    • Market Overview
    • Market Revenues
      • TABLE 34: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 4: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
    • Market Shares
      • TABLE 35: GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)
      • FIGURE 5: GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)
  • PROPHYLACTIC VACCINES
    • Market Overview
    • Market Revenues
      • TABLE 36: GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 6: GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
    • Market Shares
      • TABLE 37: GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)
      • FIGURE 7: GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)
  • INDUSTRY STRUCTURE
  • PROPHYLACTIC CANCER VACCINES
    • Market Leaders
      • TABLE 38: LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2013
    • Market Shares
      • TABLE 39: GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)
      • FIGURE 8: GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)
  • THERAPEUTIC CANCER VACCINES
    • Market Leader
      • TABLE 40: LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2013
    • Market Share
      • TABLE 41: GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)
      • FIGURE 9: GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)

CHAPTER 7 - MARKET BY CANCER TYPE

  • GLOBAL MARKET BY CANCER TYPE
  • MARKET REVENUES
    • TABLE 42: GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2019 ($ MILLIONS)
    • FIGURE 10: GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2012-2019 ($ MILLIONS)
  • MARKET SHARES
    • TABLE 43: GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)
    • FIGURE 11: GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)
  • PROSTATE CANCER
    • Market Overview
    • Market Revenues
      • TABLE 44: GLOBAL MARKET FOR PROSTATE CANCER VACCINES, THROUGH 2019 ($ MILLIONS)
      • FIGURE 12: GLOBAL MARKET FOR PROSTATE CANCER VACCINES, 2012-2019 ($ MILLIONS)
  • LIVER CANCER
    • Market Overview
    • Market Revenues
      • TABLE 45: GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 13: GLOBAL MARKET FOR LIVER CANCER VACCINES, THROUGH 2019 ($ MILLIONS)
  • CERVICAL CANCER VACCINES
    • Market Overview
    • Market Revenues
      • TABLE 46: GLOBAL MARKET FOR CERVICAL CANCER VACCINES, THROUGH 2019 ($ MILLIONS)
      • FIGURE 14: GLOBAL MARKET FOR CERVICAL CANCER VACCINES, 2012-2019 ($ MILLIONS)

CHAPTER 8 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 47: SIGNIFICANT PATENTS BY YEAR JAN. 2010 TO JUNE 2014 (NO.)
    • FIGURE 15: SIGNIFICANT PATENTS BY YEAR, JAN. 2010 TO JUNE 2014 (NO.)
  • PATENTS BY TYPE/CATEGORY
    • TABLE 48: PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)
    • FIGURE 16: PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)
  • PATENTS BY COMPANY
    • TABLE 49: U.S. PATENTS BY COMPANY, JAN. 2010 TO JUNE 2014 (NO.)
  • PATENTS BY PATENT HOLDER'S COUNTRY
    • TABLE 50: U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)
    • FIGURE 17: U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)
    • TABLE 51: PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)
    • FIGURE 18: PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)
  • PATENTS BY ASSIGNEE TYPE
    • TABLE 52: PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)
    • FIGURE 19: PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)

CHAPTER 9 - CURRENT SITUATION

  • FACTORS AFFECTING CANCER VACCINES
    • INCREASING PREVALENCE OF CANCER
    • AGING POPULATION
    • LIFESTYLE CHANGES
    • APPROVALS FOR ADDITIONAL INDICATIONS
    • COMPETITION
    • MANUFACTURERS' STRATEGIES

CHAPTER 10 - COMPANY PROFILES

  • ADAMIS PHARMACEUTICALS CORP.
  • ADURO BIOTECH INC.
  • ADVANTAGENE INC.
  • ADVAXIS INC.
  • ALPHAVAX HUMAN VACCINES INC.
  • ALTOR BIOSCIENCE CORP.
  • ANTIGEN EXPRESS INC.
  • BAVARIAN NORDIC A/S
  • BELLICUM PHARMACEUTICALS
  • BIOVEST INTERNATIONAL
  • CELLDEX THERAPEUTICS
  • CUREVAC GMBH
  • DENDREON
  • EMD SERONO
  • GALINA BIOPHARMA
  • GENEXINE INC.
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE INC.
  • GRADALIS INC.
  • HEAT BIOLOGICS INC.
  • IMMUNE CELL THERAPY INC. (ICT)
  • IMMUNICUM
  • IMMUNOFRONTIER INC.
  • IMMUNOVATIVE THERAPIES LTD.
  • INOVIO PHARMACEUTICALS
  • ISA PHARMACEUTICALS
  • KAEL-GEMVAX CO. LTD.
  • MERCK & CO.
  • NEWLINK GENETICS CORP.
  • NOVARX CORP.
  • ONCOTHYREON
  • ONCOVIR INC
  • OXFORD BIOMEDICA
  • SOTIO AS
  • UBIVAC LLC
  • VICAL INC.
  • VACCINOGEN INC.
  • VAXON BIOTECH

CHAPTER 11 - ACRONYMS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: HISTORY OF CANCER AND ITS MANAGEMENT
    • TABLE 2: ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS)
    • TABLE 3: GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012
    • TABLE 4: ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
    • TABLE 5: ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
    • TABLE 6: ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS)
    • TABLE 7: ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS)
    • TABLE 8: ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS)
    • TABLE 9: ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012
    • TABLE 10: ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012
    • TABLE 11: ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012
    • TABLE 12: REGULATORY APPROVALS OF CANCER VACCINES, THROUGH JULY 2014
    • TABLE 13: PRODUCT RECALLS, JAN. 2010 TO JULY 2014
    • TABLE 14: SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED FROM JAN. 2010 TO JULY 2014
    • TABLE 15: CLINICAL TRIALS FOR PROSTATE CANCER VACCINES (NO.)
    • TABLE 16: SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT
    • TABLE 17: CLINICAL TRIALS FOR BREAST CANCER VACCINES (NO.)
    • TABLE 18: SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT
    • TABLE 19: CLINICAL TRIALS FOR CERVICAL CANCER VACCINES (NO.)
    • TABLE 20: SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT
    • TABLE 21: CLINICAL TRIALS FOR LIVER CANCER VACCINES (NO.)
    • TABLE 22: SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT
    • TABLE 23: CLINICAL TRIALS FOR LUNG CANCER VACCINES (NO.)
    • TABLE 24: SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER
    • TABLE 25: CLINICAL TRIALS FOR STOMACH CANCER VACCINES (NO.)
    • TABLE 26: SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT
    • TABLE 27: CLINICAL TRIALS FOR COLORECTAL CANCER VACCINES (NO.)
    • TABLE 28: SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT
    • TABLE 29: CLINICAL TRIALS FOR ESOPHAGEAL CANCER VACCINES (NO.)
    • TABLE 30: SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT
    • TABLE 31: GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 32: GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)
    • TABLE 33: GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 34: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 35: GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)
    • TABLE 36: GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 37: GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)
    • TABLE 38: LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2013
    • TABLE 39: GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)
    • TABLE 40: LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2013
    • TABLE 41: GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)
    • TABLE 42: GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2019 ($ MILLIONS)
    • TABLE 43: GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)
    • TABLE 44: GLOBAL MARKET FOR PROSTATE CANCER VACCINES, THROUGH 2019 ($ MILLIONS)
    • TABLE 45: GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 46: GLOBAL MARKET FOR CERVICAL CANCER VACCINES, THROUGH 2019 ($ MILLIONS)
    • TABLE 47: SIGNIFICANT PATENTS BY YEAR JAN. 2010 TO JUNE 2014 (NO.)
    • TABLE 48: PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)
    • TABLE 49: U.S. PATENTS BY COMPANY, JAN. 2010 TO JUNE 2014 (NO.)
    • TABLE 50: U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)
    • TABLE 51: PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)
    • TABLE 52: PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 1: GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2012-2019 ($ MILLIONS)
    • FIGURE 2: GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)
    • FIGURE 3: GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 4: GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 5: GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)
    • FIGURE 6: GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 7: GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)
    • FIGURE 8: GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)
    • FIGURE 9: GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)
    • FIGURE 10: GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2012-2019 ($ MILLIONS)
    • FIGURE 11: GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)
    • FIGURE 12: GLOBAL MARKET FOR PROSTATE CANCER VACCINES, 2012-2019 ($ MILLIONS)
    • FIGURE 13: GLOBAL MARKET FOR LIVER CANCER VACCINES, THROUGH 2019 ($ MILLIONS)
    • FIGURE 14: GLOBAL MARKET FOR CERVICAL CANCER VACCINES, 2012-2019 ($ MILLIONS)
    • FIGURE 15: SIGNIFICANT PATENTS BY YEAR, JAN. 2010 TO JUNE 2014 (NO.)
    • FIGURE 16: PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)
    • FIGURE 17: U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)
    • FIGURE 18: PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)
    • FIGURE 19: PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)
Back to Top